Tracelyn Freeman1, Carlo S Legasto1,2, M Alexandra Schickli1, Eric M McLaughlin3, Pierre Giglio4, Vinay Puduvalli4, Javier Gonzalez4,5. 1. Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA. 2. Department of Pharmacy, University of California San Francisco, San Francisco, California, USA. 3. Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA. 4. Department of Neuro-Oncology, The Ohio State University, Columbus, Ohio, USA. 5. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare malignancy with few treatment options. One regimen used for induction is rituximab, high-dose methotrexate (HD-MTX), procarbazine, and vincristine (R-MPV). A common institutional practice is removing vincristine (VCR) from this regimen due to its poor CNS penetration and associated toxicities. The aim of this study was to evaluate how the omission of VCR from HD-MTX-based induction impacted clinical outcomes. METHODS: In a retrospective review, patients with PCNSL who received HD-MTX-based induction therapy between January 1, 2010 and May 31, 2018 were evaluated. Patients were stratified according to treatment into 2 groups, VCR-containing therapy versus no VCR. The primary endpoint was complete response (CR) rate following the completion of induction chemotherapy. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse event rate. RESULTS: Twenty-nine patients were included: 16 patients in the VCR group and 13 in the non-VCR group. A CR was achieved in 7 (44%) and 5 (38%) (odds ratio [OR] = 1.24; 95% confidence interval [CI]: 0.28-5.53) patients, respectively. Median OS was 85.3 (95% CI: 20.2-85.3) versus 67.1 months (95% CI: 10.5-NR) and median PFS was 60.7 (95% CI: 9.4-NR) versus 23.7 months (95% CI: 4.7-NR) in the VCR group versus non-VCR group, respectively. The incidence of any grade peripheral neuropathy was higher in the VCR group. CONCLUSIONS: CR rate, OS, and PFS were similar between groups regardless of VCR inclusion. Adverse events were higher in the VCR group. Larger studies are required to further evaluate the efficacy of VCR in PCNSL induction regimens. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology 2020.
BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare malignancy with few treatment options. One regimen used for induction is rituximab, high-dose methotrexate (HD-MTX), procarbazine, and vincristine (R-MPV). A common institutional practice is removing vincristine (VCR) from this regimen due to its poor CNS penetration and associated toxicities. The aim of this study was to evaluate how the omission of VCR from HD-MTX-based induction impacted clinical outcomes. METHODS: In a retrospective review, patients with PCNSL who received HD-MTX-based induction therapy between January 1, 2010 and May 31, 2018 were evaluated. Patients were stratified according to treatment into 2 groups, VCR-containing therapy versus no VCR. The primary endpoint was complete response (CR) rate following the completion of induction chemotherapy. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse event rate. RESULTS: Twenty-nine patients were included: 16 patients in the VCR group and 13 in the non-VCR group. A CR was achieved in 7 (44%) and 5 (38%) (odds ratio [OR] = 1.24; 95% confidence interval [CI]: 0.28-5.53) patients, respectively. Median OS was 85.3 (95% CI: 20.2-85.3) versus 67.1 months (95% CI: 10.5-NR) and median PFS was 60.7 (95% CI: 9.4-NR) versus 23.7 months (95% CI: 4.7-NR) in the VCR group versus non-VCR group, respectively. The incidence of any grade peripheral neuropathy was higher in the VCR group. CONCLUSIONS: CR rate, OS, and PFS were similar between groups regardless of VCR inclusion. Adverse events were higher in the VCR group. Larger studies are required to further evaluate the efficacy of VCR in PCNSL induction regimens. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology 2020.
Authors: Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter Journal: Blood Date: 2015-01-07 Impact factor: 22.113
Authors: Stewart J Kellie; Draga Barbaric; Pauline Koopmans; John Earl; Deborah J Carr; Siebold S N de Graaf Journal: Cancer Date: 2002-03-15 Impact factor: 6.860
Authors: Catherine A Burkhart; Fujiko Watt; Jayne Murray; Marina Pajic; Anatoly Prokvolit; Chengyuan Xue; Claudia Flemming; Janice Smith; Andrei Purmal; Nadezhda Isachenko; Pavel G Komarov; Katerina V Gurova; Alan C Sartorelli; Glenn M Marshall; Murray D Norris; Andrei V Gudkov; Michelle Haber Journal: Cancer Res Date: 2009-08-04 Impact factor: 12.701
Authors: Patrick G Morris; Denise D Correa; Joachim Yahalom; Jeffrey J Raizer; David Schiff; Barbara Grant; Sean Grimm; Rose K Lai; Anne S Reiner; Kathy Panageas; Sasan Karimi; Richard Curry; Gaurav Shah; Lauren E Abrey; Lisa M DeAngelis; Antonio Omuro Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Ajay Gogia; Chandan K Das; Lalit Kumar; Atul Sharma; Akash Tiwari; M C Sharma; Soumya Mallick Journal: South Asian J Cancer Date: 2018 Jul-Sep